No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BIIB Biogen
- 221.500
- -1.250-0.56%
Close May 10 16:00 ET
- 220.510
- -0.990-0.45%
Post 19:45 ET
32.25BMarket Cap27.69P/E (TTM)
223.950High220.010Low655.15KVolume222.760Open222.750Pre Close145.48MTurnover0.45%Turnover Ratio27.79P/E (Static)145.60MShares319.76052wk High2.12P/B32.13BFloat Cap189.44052wk Low--Dividend TTM145.05MShs Float480.180Historical High--Div YieldTTM1.77%Amplitude2.625Historical Low222.048Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Jeff Auxier's Firm Dissolves Textainer Group Position, Trims Biogen
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Redburn Atlantic Adjusts Price Target on Biogen to $235 From $275, Keeps Neutral Rating
Biogen (BIIB) has an average outperform rating and a price target range of $200 to $350, according to analysts polled by Capital IQ. Price: 218.82, Change: -0.10, Percent Change: -0.05
Eli Lilly Alzheimer's Therapy Set for June FDA AdCom Meeting
Biogen Is Maintained at Buy by HSBC
Biogen Is Maintained at Buy by HSBC
HSBC Adjusts Price Target on Biogen to $342 From $339, Maintains Buy Rating
Biogen (BIIB) has an average outperform rating and a price target range of $200 to $350, according to analysts polled by Capital IQ. Price: 216.17, Change: +2.66, Percent Change: +1.25
Comments
Tesla, Visa and Boeing are popping in pre market after reporting their earnings.
Specifically for Tesla, it’s quite amazing that it is rallying off a very poor earnings.
Sometimes, the market rallies on bad earnings could be because the bad results weren’t as bad as previously feared. Sometimes, peope buy into the “future growth” theory.
Whether all these rebounds are dead cat bounces, it remains to be seen.
PS: definitely not complaining about this pop
$SPDR S&P 500 ETF(SPY.US$ $S&P 500 Index(.SPX.US$ $Visa(V.US$ $Boeing(BA.US$ $Texas Instruments(TXN.US$ $Biogen(BIIB.US$ $Airbnb(ABNB.US$ $Bank of America(BAC.US$ $Disney(DIS.US$ $Apple(AAPL.US$ $Meta Platforms(META.US$ $Microsoft(MSFT.US$ $NVIDIA(NVDA.US$ $Taiwan Semiconductor(TSM.US$ $Super Micro Computer(SMCI.US$ $Coinbase(COIN.US$ $Alphabet-A(GOOGL.US$
Specifically for Tesla, it’s quite amazing that it is rallying off a very poor earnings.
Sometimes, the market rallies on bad earnings could be because the bad results weren’t as bad as previously feared. Sometimes, peope buy into the “future growth” theory.
Whether all these rebounds are dead cat bounces, it remains to be seen.
PS: definitely not complaining about this pop
$SPDR S&P 500 ETF(SPY.US$ $S&P 500 Index(.SPX.US$ $Visa(V.US$ $Boeing(BA.US$ $Texas Instruments(TXN.US$ $Biogen(BIIB.US$ $Airbnb(ABNB.US$ $Bank of America(BAC.US$ $Disney(DIS.US$ $Apple(AAPL.US$ $Meta Platforms(META.US$ $Microsoft(MSFT.US$ $NVIDIA(NVDA.US$ $Taiwan Semiconductor(TSM.US$ $Super Micro Computer(SMCI.US$ $Coinbase(COIN.US$ $Alphabet-A(GOOGL.US$
From YouTube
5
5
Morning Movers
Gapping up
$Tesla(TSLA.US$ stock soared 12% following the announcement of earlier releases for "more affordable" car versions, despite first-quarter results falling short of Wall Street estimates.
$AT&T(T.US$ stock increased by 3.6% after reporting stronger-than-expected subscriber growth and surpassing free cash flow growth in the first quarter.
$Visa(V.US$ stock grew 2.4% as the credit card company's second...
Gapping up
$Tesla(TSLA.US$ stock soared 12% following the announcement of earlier releases for "more affordable" car versions, despite first-quarter results falling short of Wall Street estimates.
$AT&T(T.US$ stock increased by 3.6% after reporting stronger-than-expected subscriber growth and surpassing free cash flow growth in the first quarter.
$Visa(V.US$ stock grew 2.4% as the credit card company's second...
22
1
... 
The pharma giant $Eli Lilly and Co(LLY.US$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...
70
Despite significant insider buying, Biogen's performance last year was worse than the annualised loss of 6% over the last half decade. Investors are advised to ensure they are buying a high quality business, as Biogen is showing 2 warning signs in investment analysis.
Wedbush Securities analyst Laura Chico suggests that Wall Street needs to reset its projections for Leqembi, and Biogen's turnaround story remains a work in progress. Biogen's CEO, Chris Viehbacher, sees Alzheimer's as the core franchise of Biogen going forward.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Dramericanjesus : Tesla used a bullshit stock pump to keep it's stock price afloat after horrendous numbers. Some intern did a 5 minute mockup of a ride hailing service which will have a shitload of regulatory hurdles to overcome and is probably.no where near ready to deploy.
Shroomie Dramericanjesus: that's a ceo that I want in my portfolio
Gary Investz : almost fell asleep watching his video
EverDust : Elon Musk is willing to do anything to secure his 56b compensation package, by pumping up stocks with unrealistic expectations, even the executives left one by one. That one stock to stay away from.
MonkeyGee : at the end of the day, the news doesn't matter. The AI will move the stock in the direction with the least positions.